Thalidomide Combined with MP Regimen as Initial Therapy for 23 Cases with Multiple Myeloma
LIANG Min,TIAN Juan(The First Affiliated Hospital of Jishou University,Jishou 416000,China)
[Purpose] To investigate the response and toxicity of thalidomide combined with MP regimen as initial therapy for multiple myeloma.[Methods] From Feb 2004 to Jan 2007,47 cases with untreated multiple myeloma were randomly divided into treatment group(n=23)and control group(n=24).Patients in both growps received MP regimen for 6～8 cycles.In addition,patients in treatment group received thalidomide oral administration at the same time.[Results] The overall response rate in treatment group and in control group were 78.3% and 50.0%(P=0.044)respectively.The progression free survival at 2-year,3-year and median progression free survival in treatment group and in control group were 55.9% vs 45.8%,21.0% vs 4.2% and 27 months vs 23 months(P=0.048).The overall survival at 2-year,3-year and median overall survival in treatment group and in control group were 86.5% vs 83.3%,73.7% vs 48.4% and 43 months vs 33 months(P=0.039).The incidence of hematologic toxicity and numbness of extermity in treatment group were higher than that in control group(P0.05).[Conclusions] Thalidomide combined with MP regimen can improve the progression free survival and overall survival for initial treated patients with multiple myeloma,and the toxicity is tolerable.